These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Single center experience of 1500 kidney transplants. Park K, Kim YS, Kim SI, Kim MS, Moon JI. Transplant Proc; 1998 Nov; 30(7):3088-9. PubMed ID: 9838362 [No Abstract] [Full Text] [Related]
11. Impact of cyclosporine dosing frequency on graft function and survival after the conversion from sandimmun to neoral in stable kidney transplanted patients. Sampaio EL, Park SI, Felipe CR, Silva HT, Pestana JO. Transplant Proc; 2002 Dec; 34(8):3153-61. PubMed ID: 12493405 [No Abstract] [Full Text] [Related]
12. Long-term comparison of tacrolimus and cyclosporine-based immunosuppression in kidney recipients with grafts from non-heart-beating cadaver donor. Kinukawa T, Ohshima S, Ono Y, Fujita T, Hattori R, Tanaka K. Transplant Proc; 1998 Jun; 30(4):1227-9. PubMed ID: 9636498 [No Abstract] [Full Text] [Related]
13. Risk of acute cellular rejection after azathioprine withdrawal in stable renal allograft recipients on cyclosporine, azathioprine, and prednisone. Fabrega AJ, Roy G, Reynolds L, Corwin C, Hunsicker L. Transplant Proc; 1998 Jun; 30(4):1335-6. PubMed ID: 9636543 [No Abstract] [Full Text] [Related]
14. Long-term results of kidney grafts surviving beyond the first year: comparison of cyclosporine-based regimens with the azathioprine and steroid regimen. Rizzolo M, Puggia R, Maresca MC, Calconi G, Vianello A. Transplant Proc; 1998 Aug; 30(5):1751-2. PubMed ID: 9723266 [No Abstract] [Full Text] [Related]
15. Long-term follow-up (5 and 10 years) in recipients of HLA identical living related donor kidney grafts receiving continuous cyclosporine compared with azathioprine. MacDonald AS, Belitsky P, Bitter-Suermann H, Lawen J, MacSween M, Kiberd B, West K, McAlister VC. Transplant Proc; 1997 Aug; 29(1-2):190. PubMed ID: 9122958 [No Abstract] [Full Text] [Related]
16. Use of Markov modeling for evaluating the cost-effectiveness of immunosuppressive therapies in renal transplant recipients. Lewis RL, Canafax DM, Pettit KG, DiCesare J, Kaniecki DJ, Arnold RJ, Roberts MS. Transplant Proc; 1996 Aug; 28(4):2214-7. PubMed ID: 8769203 [No Abstract] [Full Text] [Related]
17. Complete withdrawal of immunosuppression in kidney allograft recipients: a prospective study in rhesus monkeys. Jonker M, van den Hout Y, Neuhaus P, Ringers J, Kuhn EM, Bruijn JA, Schuurman HJ, Noort R, Bontrop RE, Claas FH, van Rood JJ. Transplant Proc; 1998 Aug; 30(5):2451-3. PubMed ID: 9723534 [No Abstract] [Full Text] [Related]
18. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function. Sumrani N, Hong JH, DiBenedetto A, Clayton R, Miles AM, Markell MS, Distant DA, Fleishhacker J, Sommer BG. Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289 [No Abstract] [Full Text] [Related]